Printer Friendly

PAVmed Seeks US FDA Nod for PortIO Intraosseous Infusion System.

M2 PHARMA-December 21, 2016-PAVmed Seeks US FDA Nod for PortIO Intraosseous Infusion System


- US-based medical device company PAVmed Inc. (NASDAQ: PAVM) has filed a 510(k) premarket notification submission with the US Food and Drug Administration for its first product, the PortIO Intraosseous Infusion System, the company said.

The PortIO Intraosseous Infusion System consists of an implantable vascular access device and insertion kit.

Instead of a catheter located in a vein, it has a short extension from the device, which a physician inserts into a bone, leaving the device to reside completely beneath the skin.

This allows direct access to the bone marrow, which is a well-established route for the delivery of medications, fluids and other substances.

PortIO can be inserted and removed near-percutaneously without requiring a surgical pocket or significant dissection and will not require confirmation of the position of the tip by x-ray or other means.

Once in place, the device can be accessed by the nurse through the skin using the same techniques as existing implantable ports.

((Comments on this story may be sent to

COPYRIGHT 2016 Normans Media Ltd.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2016 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:M2 Pharma
Date:Dec 21, 2016
Previous Article:Fluor awarded USD1.2bn contract to design and build USD2bn diabetes API manufacturing facility for Novo Nordisk in North Carolina.
Next Article:Neurocrine Biosciences reports planned departure of CFO Timothy P. Coughlin.

Terms of use | Privacy policy | Copyright © 2019 Farlex, Inc. | Feedback | For webmasters